A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma (THBC002)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00440934|
Recruitment Status : Terminated (Poor patient accrual)
First Posted : February 27, 2007
Last Update Posted : May 6, 2008
|Condition or disease||Intervention/treatment||Phase|
|Carcinoma, Hepatocellular||Device: Amplitude-modulated electromagnetic fields||Phase 2|
Hepatocarcinoma (HCC) is the first cause of deaths due to cancer worldwide. More than one million two hundred thousand new patients are diagnosed each year. The prognosis of patients suffering from advanced hepatocarcinoma is poor with an average survival of less than six months. Therapies for hepatocarcinoma are limited. Resection of the primary tumor is the therapeutic approach of first choice when possible. Although this intervention results in long-term survival for some patients, only a minority of them are surgical candidates because of limitations due to tumor size, patient's overall condition or presence of hepatic cirrhosis.
Phase I data suggest that low levels of amplitude-modulated electromagnetic fields administered intrabucally with a portable and programmable device are a safe and potentially effective treatment for advanced cancer. The device is connected to a spoon-like coupler placed in the patient's mouth during treatment. Patients with advanced HCC and limited therapeutic options will be offered treatment with a combination of HCC-specific frequencies.
The patients will be offered ambulatory treatment, which will be administered three times a day for 60 min until disease progression or death.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Étude de Phase II Pour déterminer l'efficacité Des Ondes électromagnétiques de Basse intensité administrées Par Voie Buccale Dans le Traitement du Cancer du Foie avancé|
|Study Start Date :||February 2007|
|Estimated Primary Completion Date :||December 2007|
|Actual Study Completion Date :||December 2007|
- • To determine disease free survival at 4 months while receiving the experimental treatment. [ Time Frame: 4 months ]
- Response rate [ Time Frame: six months ]
- To determine the influence of the treatment on the hepatic function of patients with a diagnosis of cirrhosis. To determine the impact of the treatment by means of electromagnetic waves on the overall survival of patients. [ Time Frame: six months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00440934
|Cabinet Médical de l'Avenue de la gare 6|
|Lausanne, Vaud, Switzerland, 1003|
|Principal Investigator:||Boris Pasche, MD, PhD||Cabinet Médical Avenue de la gare 6|